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Background
The Multi-Ethnic Study of Atherosclerosis (MESA) showed that the addition of coronary artery calcium (CAC) to traditional risk factors improves risk classification, particularly in intermediate risk asymptomatic patients with LDL cholesterol levels <160 mg/dL. However, the
cost-effectiveness of incorporating CAC into treatment decision rules has yet to be clearly
delineated.

Objective
To model the cost-effectiveness of CAC for cardiovascular risk stratification in asymptomatic, intermediate risk patients not taking a statin. Treatment based on CAC was compared to
(1) treatment of all intermediate-risk patients, and (2) treatment on the basis of United States
guidelines.
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Methods
We developed a Markov model of first coronary heart disease (CHD) and cardiovascular
disease (CVD) events. We modeled statin treatment in intermediate risk patients with
CAC1 and CAC100, with different intensities of statins based on the CAC score. We
compared these CAC-based treatment strategies to a “treat all” strategy and to treatment
according to the Adult Treatment Panel III (ATP III) guidelines. Clinical and economic outcomes were modeled over both five- and ten-year time horizons. Outcomes consisted of
CHD and CVD events and Quality-Adjusted Life Years (QALYs). Sensitivity analyses considered the effect of higher event rates, different CAC and statin costs, indirect costs, and
re-scanning patients with incidentalomas.

Results
We project that it is both cost-saving and more effective to scan intermediate-risk patients
for CAC and to treat those with CAC1, compared to treatment based on established riskassessment guidelines. Treating patients with CAC100 is also preferred to existing guidelines when we account for statin side effects and the disutility of statin use.

Conclusion
Compared to the alternatives we assessed, CAC testing is both effective and cost saving as
a risk-stratification tool, particularly if there are adverse effects of long-term statin use. CAC
may enable providers to better tailor preventive therapy to patients' risks of CVD.

Introduction
Atherosclerotic cardiovascular disease (CVD), including coronary heart disease (CHD) and
stroke, costs the United States an estimated $315 billion annually [1]. Cardiologists rely heavily
on risk prediction models to identify and treat patients who are at risk for CVD events [2–7].
However, heterogeneity between traditional risk factors, subclinical atherosclerosis, and clinical
outcomes is well documented [8,9]. This discordance is greatest among patients classified as
“intermediate-risk”, and this has motivated a debate about whether better markers of risk are
needed to guide treatment, or alternatively, whether universal treatment with statins is preferred, in light of the growing availability of low-cost generic statins [10]. Coronary artery calcium (CAC) measurement has proven useful for prognostication, discrimination, calibration,
and reclassification for CHD and CVD. Studies such as the Multi-Ethnic Study of Atherosclerosis (MESA) and the Heinz Nixdorf Recall (NHR) Study have shown that individuals with elevated CAC have a 9–16 fold higher risk of CHD events compared to those with CAC = 0. A
growing body of evidence shows that at least two-thirds of events are concentrated among the
one fourth of the population with CAC100, a predictive value not seen with any other biomarker [8,9,11,12]. Recent prospective studies show that the use of CAC is associated with a
net reclassification improvement for one-quarter of the whole population, and notably, in half
of patients at intermediate-risk [13,14]. Although there is strong evidence for the ability of
CAC to appropriately risk stratify patients, consensus on the cost-effectiveness of testing for
CAC, relative to other risk assessment and treatment strategies, is not clearly established. In
this study, we test the hypothesis that incorporating the results of a one-time CAC study
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among asymptomatic patients with intermediate-risk scores is a cost-effective means of primary CHD and CVD prevention, compared to (1) the treatment of all intermediate-risk patients,
and (2) treatment based on Adult Treatment Panel III guidelines (ATP III; the current guideline at the time of this study was planned) [15]. This hypothesis is based on evidence that CAC
testing improves the allocation of treatment to patients at the greatest absolute risk for CHD
and CVD events, while avoiding pharmacotherapy in low-risk patients. Tailoring the use of
statins to high-risk patients may be beneficial, given the potential for adverse side effects of
from statin use [15]. Moreover, some patients may prefer to avoid medication, and instead use
an alternative lifestyle-focused strategy for primary prevention, and therefore will experience
disutility from long-term statin use [16].

Methods
Patient Population
We simulated an intermediate-risk subpopulation from the Multi-Ethnic Study of Atherosclerosis (MESA) (ClinicalTrials.gov registration number: NCT00005487). MESA is a communitybased, prospective cohort study designed to investigate the prevalence, correlates, and progression of subclinical CVD in individuals without known CVD at baseline. Further information
about the MESA study methods and the baseline clinical characteristics of our study population are provided in S1 Table. For this study, we selected MESA participants with intermediate
ATP III Framingham Risk Scores of 6–20%, LDL-cholesterol levels <160 mg/dL, no current
use of statins at the beginning of MESA study enrollment and no prior CHD or CVD events.
We excluded patients with diabetes because the ATP III guidelines viewed this as a risk factor
that requires treatment. The MESA Publications and Presentations Committee reviewed and
approved this study.

Model Structure
We developed a Markov model using TreeAge Pro 2011 healthcare software (Williamstown,
MA). Our model simulated the clinical and economic effects of using a one-time CAC study to
guide the treatment of intermediate-risk patients, compared to an ATP III risk-stratification
strategy and a treat-all scenario, in which all intermediate-risk patients are advised to use statins. The model compared outcomes within the same cohort of patients, as if they were treated
on the basis of CAC, versus the ATP III and treat-all strategies. For each strategy, we simulated
outcomes over both five- and ten-year time horizons. Use of a five-year horizon aligned the
model with the length of statin trials and the recommendation for CAC testing in five-year intervals for asymptomatic patients [17,18]. The ten-year horizon aligned the model with the
guideline-recommended ten year risk estimate, and accounted for the likely accrual of statin
benefits over the longer-term.
We assessed the use of CAC to guide two treatment strategies. The first strategy recommended statin treatment in patients with CAC 1, and the second strategy recommended statins to patients with CAC 100. In the first strategy, patients with CAC scores of 1–100 were
advised to begin moderate intensity statin therapy. In both CAC strategies, patients with
CAC100 were advised to begin intensive statin therapy. Fig. 1 provides a conceptual overview
of the model.
ATP III eligibility was modeled strictly following the guidelines. Eligibility was therefore
based on risk factors such as LDL cholesterol levels, as well as absolute 10-year risks. When
treatment was tied to CAC, CAC trumped ATP III-based treatment recommendations. For example, if a person was eligible for a statin by ATP III criteria, a statin was not prescribed in the
CAC scenario if CAC = 0. In determining final ATP III treatment decisions with respect to
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Fig 1. Schematic of the risk assessment and treatment strategies compared. * Patients with 1CAC<100 are advised to initiate standard statin
therapy, which is assumed to provide a mean 35% reduction in the relative risk of CVD events. Patients with CAC100 are advised to begin intensive
therapy, which provides a mean 45% reduction in the relative risk of CVD events.
doi:10.1371/journal.pone.0116377.g001

“optional” LDL-C goals, we used a random number generator to assign a random 50% of patients who would not have been treated using standard ATP III LDL-C treated goals to statin
treatment to achieve their “optional” ATP-III LDL-C goals. We then bootstrapped this randomization 100 times to determine the final ATP III statin treatment population. This randomization reflects clinical practice were only some patients with lower LDL-C levels are
treated with statins to achieve even lower “optional” LDL-C levels.
We considered both CHD and CVD events as outcomes, consistent with the focus of ATP
III guidelines and the new guidelines, respectively [2,3]. For the purpose of this study, CHD
events consist of myocardial infarction, angina pectoris and resuscitated cardiac arrest; CVD
events include all CHD events plus stroke and other cardiovascular death. We did not include
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intra-parenchymal hemorrhage, subarachnoid hemorrhage, or known non-atherosclerotic/
non-infarct stroke. The primary outcome of interest was a first CHD or CVD event. Patients
cycled through the model until experiencing an event or expiring from another cause. The
model is run for five or ten cycles (depending on the time horizon), where one cycle represents
one year of costs and health outcomes. Patients cycle through the model until they reach an absorbing state, which is a first CHD or CVD event. Patients who survive and accrue QALYs experience a quality-of-life decrement after the event. This decrement is assumed to diminish
linearly over a two-year period following the event. All costs and outcomes were discounted annually at 3%.
We calculated effects based on two approaches of valuing health outcomes. The first valued
the incremental effectiveness of CAC testing in terms of averted first CVD events, where the
outcome was a binary variable (i.e., an averted event). The second valued a CVD event in terms
of a reduction in utility, measured in Quality-Adjusted Life Years (QALYs). This second approach also accounted for health utility losses due to statin complications (including potential
mortality from a severe adverse reaction), patients’ preferences for not taking statins, and side
effects from CAC testing (mortality from radiation-induced cancer).
We calibrated the model by examining event rates by CAC group, assuming all patients
were not treated (which is not a static condition of the MESA cohort), and checked that the resulting event rates equaled those observed in the MESA subsample used for this analysis.

Data Sources
Effectiveness of treatment, cost data, and transition probabilities were obtained from published
literature and the MESA study. Parameters are summarized in Table 1 along with their data
sources [20–39]. We used a combination of peer-reviewed literature, the MESA database and
expert opinion to specify parameters for the model, which are described below.

MESA Study and Event Rates
The proportion of individuals whose risk was reclassified following a CAC test is shown in
Table 2. If patients with CAC 1 were advised to use statins, CAC-based treatment increased
the proportion of the intermediate-risk population that was statin-eligible by 20%. If only patients with CAC 100 were advised to use statins, then 10.3% fewer intermediate-risk patients
were eligible for a statin.
We assumed that CHD and CVD event rates varied by CAC score. Event rates in our model
reflected mean annual rates of first events in three CAC strata (CAC = 0, 1CAC<100,
CAC100), and were based on the subpopulation from MESA chosen for this analysis. The
five-year time horizon models were based on average annual event rates over five years; the
ten-year models used average annual rates over ten years.

Effectiveness and Treatment Adherence
We modeled the benefit of statins based on the results of recent meta-analyses of randomized
controlled trials on statin efficacy [18,36]. Individuals in the treat-all scenario were assigned to
moderate statin therapy, which was modeled as providing a mean 35% relative reduction in
risk. Individuals in the ATP III arm of the model who qualified for statin treatment were also
recommended to receive moderate intensity statins. In the CAC component of the model, patients with CAC 100 were modeled as initiating intensive statin treatment and receiving a
45% relative risk reduction; those with 1CAC<100 received moderate intensity statin therapy. No statin dose adjustments or tapering of statin efficacy were assumed over the duration of
the model [19].
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Table 1. Model Parameters.
Parameters: Probabilities and
characteristics of Reclassiﬁcation
Groups

Base-Case Value /
Mean

Distribution

Person-Year Risk of CVD Event, CAC
=0

0.00406206
(0.00413593)

Beta (approximated from the
mean annual event rate)

MESA Subsample, based on 5 (10)-year event rate data

Person-Year Risk of CVD Event,
1CAC<100

0.01086766
(0.01115809)

Beta

MESA Subsample, based on 5 (10)-year event rate data

Person-Year Risk of CVD Event,
CAC100

0.01920450
(0.02060006)

Beta

MESA Subsample, based on 5 (10)-year event rate data

Person-Year Risk of CHD Event, CAC
=0

0.00201915
(0.00212544)

Beta

MESA Subsample, based on 5 (10)-year event rate data

Person-Year Risk of CHD Event,
1CAC<100

0.00839575
(0.00756866)

Beta

MESA Subsample, based on 5 (10)-year event rate data

Person-Year Risk of CHD Event,
CAC100

0.01676953
(0.01639898)

Beta

MESA Subsample, based on 5 (10)-year event rate data

RR of CHD/CVD Event, Normal dose
of statins

.6500

Triangular (min: .55, likeliest:
.65, max: .75)

Expert opinion

RR of CHD/CVD Event, High dose of
statins

.5500

Triangular (min: .45, likeliest:
.55, max: .65)

Expert opinion

Probability of death from CHD Event,
age < 65

.10000

Beta (alpha: 17, beta:153)

Lee et al. [20]

Probability of death from CHD Event,
age 65

.15714

Beta (alpha: 22, beta: 118)

Lee et al. [20]

Probability of death from CVD Event,
age < 65

.10260

Beta (alpha: 16, beta: 140)

Lee et al. [20] and MESA Subsample Data

Probability of death from CVD Event,
age 65

.16265

Beta (alpha: 23, beta: 118)

Lee et al. [20] and MESA Subsample Data

Probability of Mortality from NonCHD/Non-CVD Events

US Life Table

Probability of Mild Adverse Effect from
Statins

0.1800

Beta (alpha: 252, beta:
1148)

Lee et al. [20]

Probability of Severe Adverse Effect
from Statins

1:18000 personyears

Beta (alpha: 5.6, beta:
99994)

Lee et al. [20]

Probability of Death Given Severe
Adverse Reaction

0.0900

Beta (alpha: 7.2, beta: 73)

Lee et al. [20]

Probability of Statin Adherence, No
CAC Testing

0.5500

Triangular (min: .40, likeliest:
.55, max: 1)

Shah [22]

Probability of Statin Adherence, CAC
Testing

0.6500

Triangular (min: .50, likeliest:
.65, max: 1)

Shah [22], Kalia [23], Taylor [24], Expert opinion

Lifetime Cancer Risk Due to CTScanning Caused Radiation Exposure

0.00002

No distribution modeled

vanKempen [25]

1-year case fatality given cancer due
to radiation risk

0.6500

No distribution modeled

vanKempen [25]

Direct Medical Costs for Non-Fatal
CHD Events

$64,400.00

Ref #

Probabilities

CDC National Vital Statistics [21]

Direct Medical Costs ($US 2011)
Gamma (mean: $64,400; sd:
$32,200)

Weighted average of condition-speciﬁc 1-year direct
medical costs, where myocardial infarctions account for
49.5% of events, angina pectoris 42.6%, and Resuscitated
cardiac arrests 7.9% of events; Sources: O'Sullivan,
Bureau of Labor Statistics, and Bank of Canada [26–28];
and MESA Subsample Data
(Continued)
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Table 1. (Continued)
Parameters: Probabilities and
characteristics of Reclassiﬁcation
Groups

Base-Case Value /
Mean

Distribution

Ref #

Direct Medical Costs for Fatal CHD
Events

$49,000.00

Gamma (mean: $49,000; sd:
$24,500)

Weighted average of condition-speciﬁc 3-year direct
medical costs, where myocardial infarctions account for
49.5% of events, angina pectoris 42.6%, and Resuscitated
cardiac arrests 7.9% of events; Sources: O'Sullivan,
Bureau of Labor Statistics, and Bank of Canada [26–28];
and MESA Subsample Data

Direct Medical Costs for Non-Fatal
CVD Events

$55,700.00

Gamma (mean: $55,700; sd:
$27,850)

Weighted average of condition-speciﬁc 1-year direct
medical costs, where stroke accounts for 25.7% of events,
myocardial infarction 36.8%, angina pectoris 31.6%, and
Resuscitated cardiac arrests 5.9% of events; Sources:
O'Sullivan, Bureau of Labor Statistics, and Bank of Canada
[26–28]; and MESA Subsample Data

Direct Medical Costs for Fatal CVD
Events

$43,500.00

Gamma (mean: $43,500; sd:
$21,750)

Weighted average of condition-speciﬁc 1-year direct
medical costs, where stroke accounts for 25.7% of events,
myocardial infarction 36.8%, angina pectoris 31.6%, and
Resuscitated cardiac arrests 5.9% of events; Sources:
O'Sullivan, Bureau of Labor Statistics, and Bank of Canada
[26–28]; and MESA Subsample Data

Cost of CAC Testing

$75.00, $100.00,
and $150.00

Triangular (min: 80% of
baseline; max: 120% of
baseline)

vanKempen [25] and Expert Opinion

Annual cost of statins (both intense
and normal dose)

$50.00, $180.00,
and $1,000.00

Triangular (min: 80% of
baseline; max: 120% of
baseline)

Pletcher et al. [40]

Cost of Statin Complications (mild)

$180.00

Gamma (mean: $180; sd:
$30)

Extrapolated from Lee et al. [20] and vanKempen [25]

Cost of Statin Complications (severe)

$6,500.00

Gamma (mean: $6,500, sd:
$3,250)

Lee et al. [20]

Total cost of follow-up for incidental
non-cardiac abnormalities
(incidentaolmoas)

$250.00

Gamma (mean: $250, sd:
$125)

MacHaalany et al. [29]

Indirect Medical Costs
Average Annual Productivity Cost of a CHD Event by Age Group:
Age 40

$6,500.00

Gamma (mean: $6,500; sd:
$3,250)

Weighted average of condition-speciﬁc productivity costs,
where myocardial infarction accounts for 49.5% of events,
angina pectoris 42.6%, and Resuscitated cardiac arrests
account for 7.9% of events; Source: Grover [30]

Age 50

5,100.00

Gamma (mean: $3,100; sd:
$1,550)

Source: Grover [30]

Age 60

1,900.00

Gamma (mean: $1,900; sd:
$800)

Source: Grover [30]

Age 70

500.00

Gamma (mean: $500; sd:
$250)

Source: Grover [30]

Age 80

200.00

Gamma (mean: $200; sd:
$100)

Source: Grover [30]

Time Cost of CAC Testing (assumed
to be 1 hour)

15.20

Gamma (alpha: 1.056
lambda: .152)

Bureau of Labor Statistics [31]

Note: Linear interpolation is used to estimate the mean productivity cost of a CHD event at intermediate ages. The standard deviation of the gamma
distribution is 50% of the mean cost. For CVD events (which include stroke), the age-speciﬁc mean annual productivity costs were: $7,900 (age 40),
$6,200 (age 50), $2,300 (age 60), $600 (age 70), and $200 (age 80). These estimates were computed as a weighted average of event-speciﬁc event rates,
where the weights reﬂect the proportion of CVD events occurring in the MESA subsample (see notes to direct cost estimates for CVD events).
Health Utility Values
Age-Speciﬁc QALY Values, Healthy:
(Continued)
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Table 1. (Continued)
Parameters: Probabilities and
characteristics of Reclassiﬁcation
Groups

Base-Case Value /
Mean

Distribution

Ref #

Age 50

0.8400

No distribution modeled

Lee et al. [20]

Age 60

0.8200

No distribution modeled

Lee et al. [20]

Age 70

0.7900

No distribution modeled

Lee et al. [20]

Age 80

0.7400

No distribution modeled

Lee et al. [20]

Age 90

0.6800

No distribution modeled

Lee et al. [20]

Note: Linear interpolation was used to estimate age-speciﬁc healthy QALYs at intermediate ages.
Factors by which age-speciﬁc QALYs were multiplied to reﬂect the occurrence of adverse events or the general disutility of taking a statin:
General Disutility from Taking Statin

0.99616

Triangular (min: 0.99232,
likeliest: 0.99616, max:
1.000)

Pletcher et al. [40]

Mild Statin Complications (Annual
health utility loss)

0.9941

Triangular (min: 0.9986,
likeliest: 0.9941, max:
0.9890)

Lee et al. [20]

Severe Statin Complications (Annual
health utility loss)

0.9553

Triangular (min: 0.9808,
likeliest: 0.9553, max:
0.9233)

Lee et al. [20]

Nonfatal CHD Event (Annual health
utility loss)

0.8351

Beta (alpha: 102, beta: 20)

Weighted average of CHD condition-speciﬁc health utility
losses, obtained from Lee et al. [20]. Weights based on
events in the MESA subsample.

Nonfatal CVD Event (Annual health
utility loss)

0.8272

Beta (alpha: 180, beta: 38)

Weighted average of CVD condition-speciﬁc health utility
losses, obtained from Lee et al. [20]. Weights based on
events in the MESA subsample.

No Statin Complications

1.0000

N/A

-

Death

0.0000

N/A

-

doi:10.1371/journal.pone.0116377.t001

We assumed a 55% rate of statin adherence when treatment was guided by ATP III [22]. Research indicates that patients who visualize moderate calcium deposits in the coronary artery
have a significantly higher rate of adherence [22–24]. Therefore, the mean rate of adherence
was assumed to increase by approximately 10% among patients undergoing CAC scanning.
The case-fatality rate from a first CHD event was assumed to be 10.0% for adults under age
65, and 10.3% for non-elderly adults experiencing CVD events. We assumed a discrete increase
in the risk of CHD-attributable mortality in individuals age 65 and above [20]. In addition to
mortality from CHD events, we modeled non-CHD death using age-specific mortality rates
from the CDC’s US life table [21].

Adverse Outcomes
We modeled outcomes as both averted CHD or CVD events, valued as counts, and in QALYs.
QALYs captured losses in health due to CHD or CVD events, as well as side effects from statins
and the disutility of ongoing statin use. By disutility, we mean a patient’s inherent desire to
avoid use of a medication that may not improve health. QALYs lost from any of these outcomes were modeled as proportionate reductions in an individual’s age-specific utility associated with full health, and reflected both the severity and duration of the outcome (in relation to a
year). We modeled mild and severe statin complications, using utility decrements of 2 days and
2 weeks of lost healthy life, respectively [20]. Lastly, CAC testing entails exposure to a modest
dose of ionizing radiation (in general, approximately 1mSv) [32,33]. We assumed a modest incremental increase in lifetime cancer risk due to the CT scan used to test for CAC. We allocated
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Table 2. Re-Classiﬁcation of ATP III Assessed Statin Eligibility by CAC.
Risk as Assessed by CAC (Assumed Gold Standard)
Risks as Assessed by ATP III

Highest Risk

At Risk

Not at Risk

Total

CAC  100

1  CAC < 100

CAC = 0

(All CAC Groups)
615

Statin Eligible by ATP III:
N

193

196

226

% of Total Population

11.9%

12.1%

14.0%

N

256

294

454

% of Total Population

15.8%

18.2%

28.0%

Total (All ATP III Groups):

449

Non Statin Eligible by ATP III:
1,004

Total:
490

680

1,619

Summary Statistics
Statin Treatment Advised for CAC  1
% of Population Reclassiﬁed as At Risk or Highest Risk via CAC:

34.0%

% of Population Reclassiﬁed as Not At Risk or Highest Risk via CAC:

14.0%

Net % Reclassiﬁcation to At Risk or Highest Risk via CAC:

20.0%

Statin Treatment Advised for CAC  100
% of Population Reclassiﬁed as Highest Risk via CAC:

15.8%

% of Population Reclassiﬁed as Not Highest Risk via CAC:

26.1%

Net % Reclassiﬁcation to At Highest Risk via CAC:

−10.3%

Note: Authors’ calculations from the Multi-Ethnic Study of Atherosclerosis.
doi:10.1371/journal.pone.0116377.t002

the portion of this cumulative risk that accrues over the time horizon of the model using a linear approximation to an exponential model [25].

Incidental Findings
CAC testing may uncover incidental non-cardiac findings that warrant follow-up examinations. Studies have found that these incidental findings are detected and reviewed through follow-up tests in 4%-8% of patients. Although incidental findings could reveal early-stage
cancers, studies have found that very few non-calcified lung nodules ultimately become cancerous. Therefore, in a sensitivity analysis, we included a cost penalty for re-scanning 8% of patients in the CAC testing arm, which is based on a study of re-scanning rates in patients tested
for CAC. In this sensitivity analysis, we conservatively assumed no future health or cost benefits from the follow-up scans [29,34,35].

Costs
Cost data were obtained from literature searches and expert consultation. In selecting cost estimates, we assessed the published literature on the basis of: (1) comparability of the study’s population to ours, (2) rigor in methods used to determine incremental costs attributable to an
event, and (3) the year of the study. We ultimately selected a 2007 study using Medicare Advantage data to estimate the direct medical costs attributable to CVD events [26], and a 2002
Canadian study to determine age-specific productivity losses due to events [30]. We estimated
direct medical costs and productivity costs of a CHD or CVD event as a weighted average of
costs for specific events, using the relative frequencies of event types (e.g., angina pectoris or
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myocardial infarction) in the MESA sample as weights. Costs were converted to same-year US
dollars, where applicable, and then inflated to 2011 dollars using the CPI for Medical Care
[27,28]. We assumed the productivity cost of CAC testing to be 1 hour, valued at the US median hourly wage rate for workers over age 55 (calculated as the 2011 median weekly wage for
workers  age 55, divided by average 2011 weekly hours for workers  age 55) [31].
Base-case simulations included the direct costs of CAC testing, statins, and CHD or CVD
events, but excluded productivity costs and the cost of re-scanning patients with incidental
findings. The base-case analyses assumed a mean direct cost of $100 for a CAC test and $180
annually for the use statins (both entered into the model as triangular distributions, and varied
by +/− 20%). Costs reflect anticipated payments to providers, instead of initial charges, which
may be higher.
The main results are reported using all base-case parameter assumptions, separately for
CHD and CVD events, for scenarios where patients with CAC1 are treated, and again where
only patients with CAC100 are treated. We report incremental costs per averted event and
per QALY for these simulations.

Sensitivity Analyses
Broadly, we conducted two types of sensitivity analyses. The first was a probabilistic sensitivity
analysis that simulated uncertainty in model parameters. Table 1 specifies distributions for the
main transition probabilities, health utilities, and costs. We drew values from each distribution
for 2,000 hypothetical patients, whose outcomes we then simulated in the model, and repeated
this process over 1,000 simulations. We evaluated the mean and, for certain models, the distribution of costs and effects across the 1,000 simulations, for each strategy. We compared incremental costs and incremental effects for the three possible pairwise comparisons of
interventions. A ratio of mean incremental costs and incremental effects for a particular pair of
strategies is reported as an incremental cost-effectiveness ratio (ICER).
For the other type of sensitivity analyses, we considered changes to assumptions about specific parameters of the model, as follows. First, we considered the effect of shifting the mean
cost of a CAC test to $75, $150, and $250. Second, we changed the mean annual cost of statins
to $50 and $1,000. The higher end of the statin cost range may account for costs of follow-up
physician visits and laboratory tests associated with statin use, and the prescription of brand
name statins. Third, we included productivity costs for CAC testing and events, as well as the
downstream cost of re-examining patients with incidental non-cardiac findings.
Lastly, we considered the effect of changing CVD and CHD event rates to more closely resemble those in the general US adult population. In MESA and other prospective studies, event
rates tend to be lower than in the general population. This difference may reflect the fact that a
prerequisite for participation in MESA is survival from mortality risk factors, including CVD,
as well as the fact that some MESA subjects initiated statin use after enrolling in the study. A
comparison of event rates in MESA to nationally representative data suggests that MESA event
rates are one and one-half to two times lower than among similarly aged adults in the general
population [1]. Therefore, we compared our base-case set of results with models that assumed
annual events rates two times higher than the base-case set of MESA-derived rates. The probabilistic sensitivity analysis and sensitivity analyses on the cost parameters were repeated in the
2x MESA rates simulations.

Results
In our base-case simulations, we project that, compared to an ATP III-based treatment approach, testing all intermediate risk patients for CAC and treating those with CAC 1 averts
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Table 3. Averted CHD and CVD Events Per 1,000 Persons, Base-Case MESA Event Rates.
ATP III (Events)

Treat All (Δ Events, Compared to ATP III)

CAC* (Δ Events, Compared to ATP III)

5 Years
CHD Events

31.7

27.9 Δ = −3.9)

26.7 Δ = −5.1)

CVD Events

40.8

35.7 Δ = −5.1)

35.0 Δ = −5.8)

CHD Events

52.3

46.1 Δ = −6.2)

44.5 Δ = −7.9)

CVD Events

72.7

64.0 Δ = −8.6)

62.9 Δ = −9.8)

10 Years

Note: Simulated events per 1,000 persons, by risk assessment and treatment strategy. The results displayed in this table value outcomes in terms of
averted events, but not QALYs. Results reﬂect all base-case model assumptions and 1x MESA event rates.
* Column displays results for the scenario where patients with CAC1 are advised to initiate statins (intensive therapy for CAC100, and standard
therapy for 1CAC<100).
doi:10.1371/journal.pone.0116377.t003

an average of 5.1 additional first CHD events and 5.8 additional first CVD events per 1,000 patients over five years. Treating all intermediate risk patients averts an additional 3.9 CHD
events and an additional 5.1 CVD events per 1,000 patients over five years, in comparison to
ATP III (Table 3). Treating patients on the basis of CAC is more effective, in terms of averted
events, than treating all intermediate risk patients, because CAC enables providers to identify
candidates for intensive statin therapy, and because patients are assumed to be more adherent
to statins in the CAC strategies. The results are similar, although larger in magnitude, over a
ten-year outlook.
Table 4 shows the risk assessment and treatment strategies that would be selected under different assumptions about costs and the valuation of outcomes, using base-case MESA event
rates. The mean costs and effects calculated under each scenario are provided in S2 Table.
(Corresponding scenarios are identified by the row numbers of Table 4 and S2 Table). Screening all intermediate-risk patients and treating those with CAC 1 is generally the least costly
and most effective strategy, compared to treat all and ATP III, if the mean cost of a CAC test is
$150 or below. The break-even point, at which CAC becomes cost-ineffective compared to
ATP III, is approximately $235/test. Limiting statin therapy to patients with CAC 100 averts
fewer events than a treat all scenario, such that treating all patients is preferred to both the
CAC and ATP III strategies, if outcomes are valued only as averted events. If annual statin
costs average $1,000, treating all patients becomes too costly to implement at a willingness-topay threshold of $100,000/averted event or lower. In this scenario, ATP III is favored over
treating patients with CAC 1 and treating all intermediate-risk patients.
When outcomes are valued in QALYs, we project that a CAC-based treatment strategy is
consistently preferred to a treat-all strategy. Although more CHD and CVD events occur when
statins are recommended only in the highest-risk patients (i.e., those with CAC 100), treating
patients with CAC100 produces a greater net gain in QALYs than the treat-all strategy, because statin use is limited to individuals who are likely to experience the greatest benefit from
therapy (see Scenario 4). Statin use, and any accompanying negative side effects, is avoided in
persons with CAC below 100 in this scenario. These findings are robust to the inclusion of indirect costs and the cost of re-examining patients with incidentalomas. Table 5, which shows the
results of simulations that are based on 2x MESA event rates, also reaches similar conclusions.
Corresponding mean costs and effects are summarized in S3 Table.
Fig. 2 plots the cost-effectiveness acceptability curves for each risk assessment and treatment
strategy, for the prevention of CVD events over a ten-year horizon, when outcomes are valued
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Table 4. Results Using Base-Case MESA Event Rates.
Scenario

Mean CAC Scan Cost
($)

Mean Annual Statin Cost
($)

Time Horizon
(years)

Treat
CAC100

Valuation of
Outcomes

Decision

CHD Events
1

100

180

5

No

Events

CAC Dominates Both

2

100

180

5

No

QALYs

CAC Dominates Both

3

100

180

5

Yes

Events

Treat All Dominates ATP III

4

100

180

5

Yes

QALYs

CAC Dominates Both

5

100

180

10

No

Events

CAC Dominates Both

6

100

180

10

No

QALYs

CAC Dominates Both

7

100

180

10

Yes

Events

Treat All Cost-Effective; ICER =
$4,373

8

100

180

10

Yes

QALYs

CAC Dominates

Sensitivity Analyses on Cost Parameters
9

100

50

5

No

Events

CAC Dominates Both

10

100

50

5

No

QALYs

CAC Dominates Both

11

100

1,000

5

No

QALYs

ATP III (Status Quo)

12

100

1,000

5

Yes

QALYs

CAC Dominates Both

13

75

180

5

No

QALYs

CAC Dominates Both

14

75

180

5

Yes

QALYs

CAC Dominates Both

15

150

180

5

No

QALYs

CAC Dominates Both

16

150

180

5

Yes

QALYs

CAC Dominates Both

17

250

180

5

No

QALYs

ATP III (Status Quo)

18

Base-Case Assumptions + Indirect Costs & Incidentalomas (QALYs)

CAC Dominates Both

CVD Events
19

100

180

5

No

Events

20

100

180

5

No

QALYs

CAC Dominates Both
CAC Dominates Both

21

100

180

5

Yes

Events

Treat All Dominates ATP III

22

100

180

5

Yes

QALYs

CAC Dominates Both

23

100

180

10

No

Events

CAC Dominates Both

24

100

180

10

No

QALYs

CAC Dominates Both

25

100

180

10

Yes

Events

Treat All Dominates ATP III

26

100

180

10

Yes

QALYs

CAC Dominates Both

Sensitivity Analyses on Cost Parameters
27

100

50

5

No

Events

CAC Dominates ATP III

28

100

50

5

No

QALYs

CAC Dominates ATP III

29

100

1,000

5

No

QALYs

ATP III (Status Quo)

30

100

1,000

5

Yes

QALYs

CAC Dominates Both

31

75

180

5

No

QALYs

CAC Dominates Both

32

75

180

5

Yes

QALYs

CAC Dominates Both

33

150

180

5

No

QALYs

CAC Dominates Both

34

150

180

5

Yes

QALYs

CAC Dominates ATP III

35

250

180

5

No

QALYs

ATP III (Status Quo)

36

Base-Case Assumptions + Indirect Costs & Incidentalomas (QALYs)

CAC Dominates Both

Note: A risk assessment and treatment strategy is said to dominate if it is less costly and more effective than both of the alternative strategies to which it is
compared. Otherwise, the favored strategy may be incrementally more costly and more effective than ATP III, which was the standard of risk assessment
when this study was conducted. If the incremental cost per unit of effect is less than or equal to $50,000, but positive, the alternative intervention is
assumed to be favored, and an incremental cost-effectiveness ratio (ICER) is reported. If the ICER exceeds $50,000, ATP III is preferred. Mean costs and
effects for each strategy, which are the basis for the decisions summarized in the table, are presented in S2 Table. Scenarios are identiﬁed by the
scenario number on each row of the table.
doi:10.1371/journal.pone.0116377.t004
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Table 5. Sensitivity Analysis on Event Rate Parameters—2x MESA Event Rates.
Scenario

Mean CAC Scan
Cost ($)

Mean Annual Statin
Cost ($)

Time Horizon
(years)

Treat
CAC100

Valuation of
Outcomes

Decision

CAC Dominates Both

CHD Events
37

100

180

5

No

Events

38

100

180

5

No

QALYs

CAC Dominates Both

39

100

180

5

Yes

Events

Treat All Dominates
ATP III

40

100

180

5

Yes

QALYs

CAC Dominates Both

41

100

180

10

No

Events

CAC Dominates Both

42

100

180

10

No

QALYs

CAC Dominates Both

43

100

180

10

Yes

Events

Treat All Dominates
ATP III

44

100

180

10

Yes

QALYs

CAC Dominates Both

CVD Events
45

100

180

5

No

Events

CAC Dominates Both

46

100

180

5

No

QALYs

CAC Dominates Both

47

100

180

5

Yes

Events

Treat All Dominates
ATP III

48

100

180

5

Yes

QALYs

CAC Dominates ATP III

49

100

180

10

No

Events

CAC Dominates Both

50

100

180

10

No

QALYs

CAC Dominates Both

51

100

180

10

Yes

Events

Treat All Dominates
Both

52

100

180

10

Yes

QALYs

CAC Dominates ATP III

Note: A risk assessment and treatment strategy is said to dominate if it is less costly and more effective than both of the alternative strategies to which it is
compared. Otherwise, the favored strategy may be incrementally more costly and more effective than ATP III, which was the standard of risk assessment
when this study was conducted. If the incremental cost per unit of effect is less than or equal to $50,000, the alternative intervention is assumed to be
favored, and an incremental cost-effectiveness ratio (ICER) is reported. If the ICER exceeds $50,000, but is positive, then ATP III is preferred. Mean costs
and effects for each scenario, which are the basis for the decisions summarized in the table, are presented in S3 Table. Scenarios are identiﬁed by the
scenario number on each row of the table.
doi:10.1371/journal.pone.0116377.t005

as QALYs. The figure summarizes the distribution of the simulated results, based on the proportion of simulations that are cost-effective (measured on the vertical axis) at different willingness-to-pay thresholds (horizontal axis). The intercept of each curve with the vertical axis
represents the proportion of simulations for a given strategy that would be accepted at a willingness-to-pay threshold of $0/QALY; the intercept includes simulations for which a strategy
is both cost saving and more effective than the two other alternatives. The figure demonstrates
that approximately 75% of the CAC simulations are cost-effective at the $0/QALY threshold,
compared to the treat-all and ATP III strategies. CAC remains favored in a majority of simulations at positive willingness-to-pay thresholds.

Discussion
We investigated the cost-effectiveness of CAC testing in intermediate-risk individuals, to predict CHD and CVD risks, and to guide statin allocation. Using a Markov simulation model, we
compared a CAC strategy to treat-all and ATP III strategies for screening and treatment. We
found that CAC testing is generally less costly and more effective than these alternative strategies, particularly when we account for the effects of adverse statin reactions and the disutility of
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Fig 2. Cost-Effectiveness Acceptability Curves. Panel (a): 10-Year CVD Events, Treat CAC  1. Panel (b): 10-Year CVD Events, Treat CAC  100. Note:
The cost-effectiveness acceptability curves show the proportion of simulations (vertical axis) that are cost-effective at a given willingness-to-pay threshold
(horizontal axis). A mean CAC scanning cost of $100 and a mean statin cost of $180 is assumed in both plots (indirect costs and costs associated with
incidentalomas are not included). The vertical intercept of each cost-effectiveness acceptability curve includes simulations that are cost saving and which
result in a loss of fewer QALYs compared to the alternative scenarios. The intercept can be interpreted as the probability that a strategy would be accepted at
a willingness-to-pay threshold of $0/QALY. For example, approximately 75% of simulations in both CAC strategies would be accepted at the $0/
QALY threshold.
doi:10.1371/journal.pone.0116377.g002
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taking a statin. A CAC-based strategy permits identification of appropriate candidates for statin therapy, enables clinicians to adjust the intensity of the therapy to patients’ risk, and avoids
pharmacological intervention in a large group of truly lower risk patients.
CAC is known to be strongly predictive of absolute risks for CHD and CVD. When evaluating the effectiveness of screening and treatment strategies on the basis of averted events, treating patients with any CAC (i.e., CAC 1) was preferred to the alternative strategies we
considered. Even at a higher CAC cost of $150, which is about double the available cost of a
CAC study in certain US cities, such as Baltimore and Miami, CAC testing remained cost-effective at 1x and 2x MESA event rates. Limiting statin treatment to patients with CAC 100 prevented fewer CHD and CVD events, but reduced the number of patients who might disfavor
taking a statin, and the occurrence of adverse statin side effects. Consequently, CAC screening
and treatment of just the highest-risk patients (CAC 100) was favored when outcomes were
valued in QALYs. This result is consistent with a prior MESA study, which suggested that accounting for the adverse effects of statin use could make a treat-all strategy less attractive than
more selective treatment [40]. The American College of Cardiology and American Heart Association (ACC/AHA) recently released new cholesterol [7] and risk assessment guidelines [2],
which have important implications for this analysis. In a primary prevention patient considered for statin therapy, the 2013 ACC/AHA guidelines recommend that a risk discussion occur
if the low-density lipoprotein cholesterol level is 70–189 mg/dL and if the estimated 10-year
atherosclerotic cardiovascular disease risk is 5% or higher. The vast majority of intermediate
risk patients included in our analysis have a 10-year risk of 5% or higher under the new guidelines. Our analysis suggests that performing a CAC study could add constructively to discussions about risk and appropriate treatment. While the risk discussion is also likely to
incorporate factors that we do no model in this study, our results suggest that CAC may be
helpful in adjudicating treatment decisions, particularly when patients or providers are concerned about the disadvantages of statin use, or the appropriate intensity of therapy if treatment is initiated [5–7]. This analysis extends prior contributions to the cost-effectiveness
literature on statins and CAC. Lazar et al. concluded that a broad treatment expansion using
low-cost statins could avoid 6.3% of all CHD deaths in the United States at a favorable cost-effectiveness ratio [39]. An analysis by Sniderman et al. also compared CAC testing to a strategy
that called for broader statin therapy for primary prevention [10]. Their analyses indicated that
the number needed to treat to reduce CHD events by 23% was 70 for a treat-all with moderate
intensity statin scenario, and 43 for CAC-guided scenario. While highlighting that CAC testing
permits more efficient allocation of pharmacotherapy, by requiring statin use in fewer patients
to reduce an equal number of events, the conclusions about cost-effectiveness were limited by
the study’s assumptions. The analysis seemed to favor broad statin treatment, but assumed a
high CAC testing cost of $340, an unrealistic medication adherence rate of 100%, and no negative statin side effects or disutility from taking a medication.
A cost-effectiveness analysis by van Kempen et al. from the Rotterdam study found CAC
testing to be cost-effective for men (ICER = $48,000/QALY), but also concluded that broader
statin therapy was less costly per QALY than CAC testing [25]. Several important factors may
account for the difference between these conclusions and ours. First, the population in the Rotterdam study is older than in MESA, with a mean age of 70 among men and 74 among women.
Second, the modeling used a patient’s remaining lifetime as the analytic horizon, extrapolating
CHD incidence, as well as statin effectiveness, beyond available data to make projections over
this long analytic horizon. Third, the van Kempen study modeled the synergistic pharmacologic effect of statins, anti-hypertensives and in certain instances aspirin for CHD primary prevention, while we focused on the incremental benefit of statin use alone. Fourth, we model the
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plausible assumption that clinicians will provide high-dose statins to patients in whom very
high CAC is detected, resulting in more effective statin treatment for these patients.
Pletcher and colleagues recently published a cost-effectiveness of CAC to guide statin therapy in intermediate risk persons from MESA [40]. Using a base-case 10-year horizon, and 55year-old men and women, it was concluded that CAC could be cost-effective only in the setting
of high cost statin therapy or significant negative effects on quality of life. A CAC treatment
threshold of 0 was suggested. Our analysis clarifies the impact of using different intensities of
statin therapy their related risk reductions based on the magnitude of CAC elevation. In addition, our study adds greater clarity about thresholds for the cost of statins and CAC tests that
may make a strategy cost-prohibitive.
Our results conservatively represent the benefits of CAC testing over a period of reliable
data, and in a population that is more ethnically diverse, and representative of the US, than
prior studies. We also consider a variety of patient characteristics and policy parameters under
which testing is most likely to be cost-effective. While we consider the cost-effectiveness of testing patients for CAC based on standard willingness-to-pay thresholds, we also consider more
general thresholds (see Fig. 2). This helps to account for the fact clinicians may judge the longterm benefits of statin therapy to further offset the upfront cost of CAC scanning, and addresses a longstanding debate over the appropriateness of the $50,000 threshold in the cost-effectiveness literature [41,42]. Limitations
Our model makes assumptions about clinical outcomes, their corresponding costs and effects on patients’ quality of life, and potential correlations between parameters. We focus on
the primary prevention of CHD and CVD effects through statin use. Although modeling CVD
was important in light of the new ACC guidelines, we acknowledge that there is lack of clarity
with about which proportion are non-atherosclerotic, and therefore less responsive to
statin therapy.
We conducted probabilistic sensitivity analyses for the main cost, outcome and probability
parameters, but the distributions and ranges tested may not represent the range of possible values for all patient populations. For instance, we varied the relative risk reduction of attributable
to moderate-intensity statin statins from 25–45%, and the risk-reduction from high-dose statins from 35%-55%, based on overall estimates from meta-analyses of randomized controlled
trials. However, not vary these proportional benefits in relation to specific clinical characteristics, such as baseline LDL cholesterol levels [45]. In addition, we model the cost of CHD and
EVD events based on data from Medicare Advantage plans. Costs in Medicare Advantage populations have been reported to be lower than in the Medicare fee-for-service population, likely
due to favorable risk selection into managed care plans [43]. Moreover, the estimates in our
modeling were driven from multiple previous publications and it is important to consider that
estimates can be variable from study to study based on population characteristics and inclusion
criteria. We did not take into account any potential synergistic benefit with anti-hypertensive
regimens, and more controversially, with aspirin in certain patients, nor did we model other
potential non-CVD benefits of statin use, such as nephroprotection or prevention of dementia
[44]. In addition, a sizable percentage of patients in the MESA population were potentially
started on statin treatment subsequent to the study enrollment, and participants may also be
healthier than similarly aged adults in the US. We attempted to account for these factors by rerunning our simulations with elevated event rates.
Our model does not simulate a cohort of patients for the remainder of their lives. As such,
we did not examine the downstream impact of preventing a first CHD or CVD event, and did
not test the implications of treating patients with statins for the remainder of their lives. These
long-term consequences are difficult to estimate with existing data. We held to five- and tenyear time horizons. The 5-year horizon is most conservative and matches the typical length of
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randomized controlled trials testing the efficacy of statins. Extending the time horizon beyond
5 years takes the analysis outside of the available randomized trial data, and requires us to
make an assumption on the long-term effectiveness of statins. However, this analysis allows us
to consider the downstream benefits of statin use. Finally, we do not model the interaction of
statins with aspirin use and other primary prevention strategies.

Conclusion
The intended use population for the estimates from our study is one that is intermediate risk,
based on traditional risk factors. Using conservative parameters in a simulation model, we find
that CAC testing in intermediate-risk patients is likely to be cost-saving and more effective
than both treat all and ATP III-based strategies, over five- and ten-year time horizons. CAC
may enable providers to better refine risk based treatment decisions in intermediate-risk patients, and enhance providers’ ability to implement CVD prevention guidelines.
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